Pemetrexed
In Stock•Starting at $8 for 1 mg•Purity ≥ 98%
| CAS No. | 137281-23-3 |
|---|---|
| MDL No. | MFCD19105065 |
| MF | C20H21N5O6 |
| MW | 427.40 |
| InChI Key | WBXPDJSOTKVWSJ-ZDUSSCGKSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 1 mg | 99+% | $8 | In Stock | |
| 250 mg | 98% | $18 | In Stock | |
| 1 g | 98% +(contains <4%EtOH)(Loss on drying≤6%) | $32 | In Stock | |
| 5 g | 98% +(contains <4%EtOH)(Loss on drying≤6%) | $120 | In Stock | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Pemetrexed is an N-acylglutamic acid with the N-acyl group as 4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl. It inhibits thymidylate synthase (EC 2.1.1.45), dihydrofolate reductase (EC 1.5.1.3), and glycinamide ribonucleotide formyltransferase (EC 2.1.2.2). It functions as an antineoplastic agent, antimetabolite, and pyrrolopyrimidine, and is a N-acyl-L-glutamic acid. It is also the conjugate acid of pemetrexed(2-).
| CAS No. | 137281-23-3 |
|---|---|
| Product Name | Pemetrexed |
Biological Targets
DHFR·GART·TYMS
Associated Conditions
mesothelioma·urinary bladder cancer·ovarian carcinoma·neuroendocrine neoplasm·lymphoma·
* The information provided here is compiled from public sources and is for reference only.
